FDA Eyes Bacteria Boost for Animal Feed: Farmers Rejoice?
Published Date: 8/19/2025
Proposed Rule
Summary
Evonik Corporation wants the FDA to approve a new safe ingredient called Bacillus velezensis for animal food, which can be used for all kinds of animals. This change could help farmers and pet owners by improving animal feed options. The FDA is reviewing this petition now, so keep an eye out for updates that might affect animal food rules and safety.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Petition to Allow New Animal Feed Ingredient
The FDA filed a petition from Evonik Corporation asking to allow Bacillus velezensis as a source of viable (live) microorganisms in animal food for all species. The petition says this could help farmers and pet owners by improving animal feed options. The FDA is currently reviewing the petition, so this is a proposed change under consideration.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2025-15776 — Airworthiness Directives; Airbus Helicopters
If you fly certain Airbus AS 332L2 or EC 225LP helicopters, new safety rules are coming your way! The FAA wants you to keep doing inspections but also add a cool new upgrade to the main gearbox parts to keep things safe. You’ll need to act on this soon, and it might cost some time and money, but it’s all about keeping your chopper flying safely.
Next: 2025-15818 — Modernizing the Commission's National Environmental Policy Act Rules
The FCC wants to update its environmental review rules to make building new tech infrastructure faster and easier. This helps companies get projects done quicker, boosting competition and new technology for everyone. If you’re applying for FCC approval, expect clearer, speedier reviews soon!